Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 9, 2025 • 1:11 PM ET

Date/Time Source News Release
05/12/2025 07:35 AM EDT GlobeNewswire Alterity Therapeutics Prominently Featured at the International MSA Congress
05/07/2025 08:16 AM EDT GlobeNewswire Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
05/05/2025 07:35 AM EDT GlobeNewswire Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
04/30/2025 07:35 AM EDT GlobeNewswire Appendix 4C - Q3 FY25 Quarterly Cash Flow Report
04/28/2025 07:35 AM EDT GlobeNewswire Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
04/10/2025 07:35 AM EDT GlobeNewswire Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
04/03/2025 07:35 AM EDT GlobeNewswire Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
03/27/2025 07:25 AM EDT GlobeNewswire Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
02/10/2025 07:25 AM EST GlobeNewswire Alterity Therapeutics Raises A$40.0 million in Placement
01/30/2025 07:35 AM EST GlobeNewswire Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Page

Additional News

As of June 9, 2025 • 1:11 PM ET

Date/Time Source News Release
05/05/2025 02:00 PM EDT PRISM News PRISM Mid-Day Movers: Trial Results and FDA Fast Tracks Drive Indices Higher
02/10/2025 08:54 AM EST SeekingAlpha Alterity Therapeutics raises A$40 million
01/30/2025 09:47 AM EST Baystreet Alterity Vaults on Drug Test Results
01/30/2025 08:36 AM EST 24/7 Market News Alterity Therapeutics Reports Positive ATH434 Phase 2 Trial Results in MSA
09/30/2024 08:00 AM EDT SeekingAlpha Alterity Therapeutics appoints Abby Macnish Niven as CFO
08/25/2024 08:01 AM EDT SeekingAlpha Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more
07/18/2024 11:01 AM EDT Zacks Alterity (ATHE) Up on Interim Data From Advance MSA Study
07/17/2024 12:37 PM EDT SeekingAlpha Alterity stock climbs 8% on positive Phase 2 data for ATH434-202
04/15/2024 12:47 PM EDT SeekingAlpha BSGM, ENLV and WISA among mid-day movers
04/15/2024 08:21 AM EDT SeekingAlpha NXPL, MGRM and OCX among pre-market losers
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.